Yahoo Finance

Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

SYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed ...
Yahoo Finance

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE ® 327 (R327) at the highest tested dose of 4,000mg No serious adverse events and clinically significant changes ...
manilatimes

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated ...

Phase II trial assessed the efficacy and safety of RECCE ® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections ...